Aging
Navigate
Submit an Article
Research Paper|Volume 14, Issue 17|pp 7038—7051

The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer

Yuan Cai1, Rong Zeng2, Jinwu Peng1,3,4, Wei Liu1,5, Qingchun He6,7, Zhijie Xu1, Ning Bai8
  • 1Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 2General Surgery Department, Second Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 3Department of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China
  • 4National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 5Department of Orthopedic Surgery, The Second Hospital University of South China, Hengyang 421001, Hunan, China
  • 6Department of Emergency, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
  • 7Department of Emergency, Xiangya Changde Hospital, Changde 415000, Hunan, China
  • 8Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
* Equal contribution and co-first author
Received: May 23, 2022Accepted: August 24, 2022Published: September 12, 2022
https://doi.org/10.18632/aging.204270

Copyright: © 2022 Cai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Drug metabolism-associated genes have been clarified to play a vital role in the process of cancer cell growth and migration. Nevertheless, the correlation between drug metabolism-associated genes and gastric cancer (GC) has not been fully explored and clarified. This paper has focused on the role of aldehyde dehydrogenase 6 family member A1 (ALDH6A1), a drug metabolism-associated gene, in the immune regulation and prognosis of GC patients. Using several bioinformatics platforms and immunohistochemistry (IHC) assay, we found that ALDH6A1 expression was significantly down-regulated in GC tissues. Moreover, higher expression of ALDH6A1 was related to the better prognosis of GC patients. ALDH6A1 was also found to be involved in the regulation of several immune-associated signatures, including immunoinhibitors. In conclusion, the above results have concluded that aberrant expression of ALDH6A1 might be served as the promising predictor for prognosis and clinical immunotherapy response in GC patients.